Pfizer Inc

Chart & Performance

D1W1MN

P/E

17.40

P/S

2.20

EPS

1.42

Div Yield, %

6.82%

Shrs. gr., 5y

0.09%

Rev. gr., 5y

4.22%

Revenues

63.63b

+8.77%

Net income

8.03b

+279.00%

CFO

12.74b

+46.48%

Dividend

Jul 25, 20240.42 USD/sh

Earnings

Apr 29, 2025

Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

URL

https://www.pfizer.com/

IPO date

Jan 17, 1944

Employees

83,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	63,627,000 8.77%	58,496,000 -41.70%	100,330,000 23.43%
Cost of revenue	27,242,000	55,137,000	59,449,000
Unusual Expense (Income)
NOPBT	36,385,000	3,359,000	40,881,000
NOPBT Margin	57.18%	5.74%	40.75%
Operating Taxes	(28,000)	(1,114,000)	3,328,000
Tax Rate			8.14%
NOPAT	36,413,000	4,473,000	37,553,000
Net income	8,031,000 279.00%	2,119,000 -93.25%	31,372,000 42.74%
Dividends	(9,512,000)	(9,247,000)	(8,983,000)
Dividend yield	6.29%	5.63%	3.06%
Proceeds from repurchase of equity			(2,000,000)
BB yield			0.68%
Debt
Debt current	6,946,000	10,346,000	2,945,000
Long-term debt	56,703,000	64,164,000	34,522,000
Deferred revenue
Other long-term liabilities	23,079,000	27,241,000	26,203,000
Net debt	40,945,000	46,050,000	(334,000)
Cash flow
Cash from operating activities	12,744,000	8,700,000	29,267,000
CAPEX	(2,909,000)	(3,907,000)	(3,236,000)
Cash from investing activities	2,652,000	(32,278,000)	(15,783,000)
Cash from financing activities	(17,140,000)	26,066,000	(14,834,000)
FCF	39,884,000	(1,117,000)	36,161,000
Balance
Cash	20,477,000	12,690,000	22,732,000
Long term investments	2,227,000	15,770,000	15,069,000
Excess cash	19,522,650	25,535,200	32,784,500
Stockholders' equity	109,657,000	111,144,000	118,084,000
Invested Capital	155,702,350	162,877,800	122,618,500
ROIC	22.86%	3.13%	35.18%
ROCE	20.52%	1.78%	26.13%
EV
Common stock shares outstanding	5,700,000	5,709,000	5,733,000
Price	26.53 -7.85%	28.79 -43.81%	51.24 -13.23%
Market cap	151,221,000 -8.00%	164,362,110 -44.05%	293,758,920 -12.85%
EV	192,460,000	210,686,110	293,680,920
EBITDA	43,398,000	9,649,000	45,945,000
EV/EBITDA	4.43	21.84	6.39
Interest	3,091,000	2,209,000	1,238,000
Interest/NOPBT	8.50%	65.76%	3.03%